Lupin receives USFDA approval for Albendazole Tablets USP

Thursday brought with it an announcement from pharma company, Lupin Limited stating that it had been granted approval by United States Food and Drug Administration (USFDA) for Albendazole Tablets USP, 200 mg.

The drug which is the broad equivalent of Albenza Tablets, 200 mg, of Impax Laboratories Inc, is directed to treat parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm and cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm.

IMS Health and Quintiles' (IQVIA) MAT April 2020 data reveals that Albendazole Tablets USP had annual sales of US$ 34 million in the US.

Lupin Limited is an innovation-led transnational pharmaceutical company with its headquarters at Mumbai, India. The company develops and commercializes a broad range of branded and generic formulations, APIs and biotechnology products in more than a 100 markets across the world.

Lupin's stock was trading at Rs 908.40 on Friday at 11 am, down by 1.14 per cent or Rs 10.45 per share. The 52-week high is Rs 936.45 and the 52-week low is Rs 505 on BSE.